Should I buy or sell Gain Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GANX shares. View GANX analyst ratings or view top-rated stocks .

What is Gain Therapeutics' stock price target for 2024?

3 equities research analysts have issued twelve-month price objectives for Gain Therapeutics' shares. Their GANX share price targets range from $6.00 to $10.00. On average, they anticipate the company's stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 162.1% from the stock's current price. View analysts price targets for GANX or view top-rated stocks among Wall Street analysts .

How have GANX shares performed in 2024?

Gain Therapeutics' stock was trading at $3.27 at the beginning of the year. Since then, GANX stock has decreased by 2.8% and is now trading at $3.18. View the best growth stocks for 2024 here .

Are investors shorting Gain Therapeutics?

Gain Therapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 138,100 shares, a drop of 11.9% from the March 15th total of 156,700 shares. Based on an average trading volume of 161,800 shares, the days-to-cover ratio is currently 0.9 days. Approximately 1.0% of the company's shares are short sold. View Gain Therapeutics' Short Interest .

When is Gain Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our GANX earnings forecast .

How were Gain Therapeutics' earnings last quarter?

Gain Therapeutics, Inc. (NASDAQ:GANX) issued its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.03.

When did Gain Therapeutics IPO?

Gain Therapeutics (GANX) raised $40 million in an initial public offering on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

How do I buy shares of Gain Therapeutics?

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:GANX

Gain Therapeutics (GANX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free GANX Stock Alerts

$3.18

+0.03 (+0.95%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.00
▼
$3.23
50-Day Range: $3.09
▼
$4.82
52-Week Range: $2.00
▼
$6.19

Volume: 71,353 shs
Average Volume: 156,778 shs
Market Capitalization: $51.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.33

Get Gain Therapeutics alerts:

Gain Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 162.1% Upside
$8.33 Price Target
Short Interest: Healthy
1.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$115,800 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.17) to ($1.05) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.32 out of 5 stars

Medical Sector

288th out of 911 stocks

Pharmaceutical Preparations Industry

121st out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Gain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Gain Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.02% of the float of Gain Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Gain Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Gain Therapeutics has recently decreased by 11.87%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Gain Therapeutics does not currently pay a dividend.
Dividend Growth
Gain Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GANX.

3.0

News and Social Media Coverage

News Sentiment
Gain Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Gain Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for GANX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
3 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gain Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $115,800.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
11.00% of the stock of Gain Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.97% of the stock of Gain Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Gain Therapeutics are expected to grow in the coming year, from ($1.17) to ($1.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gain Therapeutics is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gain Therapeutics is -1.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gain Therapeutics has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Timothy Sykes

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

About Gain Therapeutics Stock (NASDAQ:GANX)

Gain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

GANX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GANX Stock News Headlines

April 2, 2024 | insidertrades.com

Gain Therapeutics, Inc. (NASDAQ:GANX) Director Buys $115,800.00 in Stock

April 17, 2024 | finance.yahoo.com

Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher

April 20, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

April 8, 2024 | finanznachrichten.de

Gain Therapeutics, Inc.: Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

April 8, 2024 | markets.businessinsider.com

Gain Therapeutics Appoints Gene Mack As CFO; Stock Falls

April 8, 2024 | globenewswire.com

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

April 4, 2024 | msn.com

Former Gildan CEO considered acquisition of Hanesbrands - Bloomberg

April 1, 2024 | finance.yahoo.com

Director Jeffrey Riley Acquires 30,000 Shares of Gain Therapeutics Inc (GANX)

April 20, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

April 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Gain Therapeutics on Promising Parkinson’s Treatment and Solid Financial Outlook

April 1, 2024 | finance.yahoo.com

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

March 28, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Gain Therapeutics Backed by Strong Financials and Promising Parkinson’s Drug Candidate GT-02287

March 27, 2024 | finanznachrichten.de

Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

March 26, 2024 | globenewswire.com

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

March 15, 2024 | globenewswire.com

Gain Therapeutics to Present at Public Ventures Discovery Day

March 5, 2024 | msn.com

EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease

March 5, 2024 | finance.yahoo.com

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

February 27, 2024 | finance.yahoo.com

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

February 27, 2024 | globenewswire.com

February 23, 2024 | benzinga.com

Gain Therapeutics Stock (NASDAQ:GANX), Short Interest Report

February 17, 2024 | finance.yahoo.com

GANX Mar 2024 7.500 call

February 16, 2024 | finanznachrichten.de

Gain Therapeutics, Inc.: Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight

February 14, 2024 | finance.yahoo.com

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

February 14, 2024 | globenewswire.com

Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight

February 7, 2024 | markets.businessinsider.com

Buy Rating for Gain Therapeutics Backed by Strong Preclinical Data and Promising Parkinson’s Candidate GT-02287

February 6, 2024 | marketwatch.com

Amgen 4Q Revenue Surges as Acquisition Boosts Results

February 6, 2024 | finance.yahoo.com

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

See More Headlines

Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GANX
CUSIP: N/A
CIK: 1819411
Web: www.gaintherapeutics.com
Phone: 301-500-1556
Fax: N/A
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.33
High Stock Price Target: $10.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +162.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,270,000.00
Net Margins: N/A
Pretax Margin: -40,210.22%
Return on Equity: -193.03%
Return on Assets: -123.21%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 3.59
Quick Ratio: 3.59

Sales & Book Value

Annual Sales: $50,000.00
Price / Sales: 1,031.59
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.97 per share
Price / Book: 3.28

Miscellaneous

Outstanding Shares: 16,220,000
Free Float: 14,436,000
Market Cap: $51.58 million
Optionable: Optionable
Beta: 0.43

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Khalid Islam Ph.D. (Age 69)
Founder & Chairman
Comp: $75k
Mr. Matthias Alder LIC. IUR. (Age 59)
LL.M., President, CEO & Director
Comp: $593k
Mr. Gianluca Fuggetta (Age 35)
VP of Finance, Senior Dir. of Corp. Reporting, Principal Acc. Off., & Principal Financial Off.
Dr. Manolo Bellotto Ph.D. (Age 53)
GM & Chief Strategy Officer
Comp: $251.99k
Dr. Joanne Taylor Ph.D.
Senior Vice President of Research
Dr. Terenzio Ignoni Pharm.D.
Senior Vice President of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GANX Stock Analysis - Frequently Asked Questions

Should I buy or sell Gain Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GANX shares.
View GANX analyst ratings or view top-rated stocks.
What is Gain Therapeutics' stock price target for 2024?: 3 equities research analysts have issued twelve-month price objectives for Gain Therapeutics' shares. Their GANX share price targets range from $6.00 to $10.00. On average, they anticipate the company's stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 162.1% from the stock's current price.
View analysts price targets for GANX or view top-rated stocks among Wall Street analysts.
How have GANX shares performed in 2024?: Gain Therapeutics' stock was trading at $3.27 at the beginning of the year. Since then, GANX stock has decreased by 2.8% and is now trading at $3.18.
View the best growth stocks for 2024 here.
Are investors shorting Gain Therapeutics?: Gain Therapeutics saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 138,100 shares, a drop of 11.9% from the March 15th total of 156,700 shares. Based on an average trading volume of 161,800 shares, the days-to-cover ratio is currently 0.9 days. Approximately 1.0% of the company's shares are short sold.
View Gain Therapeutics' Short Interest.

When is Gain Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our GANX earnings forecast.
How were Gain Therapeutics' earnings last quarter?: Gain Therapeutics, Inc. (NASDAQ:GANX) issued its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.03.
When did Gain Therapeutics IPO?: Gain Therapeutics (GANX) raised $40 million in an initial public offering on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.
How do I buy shares of Gain Therapeutics?: Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GANX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Gain Therapeutics (GANX) Stock Price, News & Analysis

Gain Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Gain Therapeutics Stock (NASDAQ:GANX)

GANX Stock Price History

GANX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

GANX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™